SK287823B6 - Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2- methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-2,4-dione and sub-maximal amount of glimepiride and use thereof - Google Patents

Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2- methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-2,4-dione and sub-maximal amount of glimepiride and use thereof Download PDF

Info

Publication number
SK287823B6
SK287823B6 SK60-2000A SK602000A SK287823B6 SK 287823 B6 SK287823 B6 SK 287823B6 SK 602000 A SK602000 A SK 602000A SK 287823 B6 SK287823 B6 SK 287823B6
Authority
SK
Slovakia
Prior art keywords
dione
pyridyl
ethoxy
methyl
benzyl
Prior art date
Application number
SK60-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK602000A3 (en
Inventor
Robin Edwin Buckingham
Stephen Alistair Smith
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10816177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK287823(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of SK602000A3 publication Critical patent/SK602000A3/sk
Publication of SK287823B6 publication Critical patent/SK287823B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK60-2000A 1997-07-18 1998-07-16 Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2- methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-2,4-dione and sub-maximal amount of glimepiride and use thereof SK287823B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9715306A GB9715306D0 (en) 1997-07-18 1997-07-18 Novel method of treatment
PCT/GB1998/002109 WO1999003476A1 (en) 1997-07-18 1998-07-16 Treatment of diabetes with thiazolidinedione and sulphonylurea

Publications (2)

Publication Number Publication Date
SK602000A3 SK602000A3 (en) 2000-07-11
SK287823B6 true SK287823B6 (sk) 2011-11-04

Family

ID=10816177

Family Applications (2)

Application Number Title Priority Date Filing Date
SK60-2000A SK287823B6 (sk) 1997-07-18 1998-07-16 Pharmaceutical composition comprising 2 to 8 mg of 5-[4-[2-(N-2- methyl-N-pyridyl)amino)ethoxy]benzyl]tiazolidin-2,4-dione and sub-maximal amount of glimepiride and use thereof
SK89-2005A SK288053B6 (sk) 1997-07-18 1998-07-16 Combination comprising 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and sub maximal amount of sulphonylurea

Family Applications After (1)

Application Number Title Priority Date Filing Date
SK89-2005A SK288053B6 (sk) 1997-07-18 1998-07-16 Combination comprising 5-[4-[2-(N-methyl-N-(2- pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione and sub maximal amount of sulphonylurea

Country Status (41)

Country Link
EP (1) EP0998291B2 (de)
JP (2) JP2001510158A (de)
KR (1) KR100680667B1 (de)
CN (1) CN1264302A (de)
AP (1) AP1318A (de)
AR (2) AR016768A1 (de)
AT (1) ATE366577T1 (de)
AU (1) AU743269B2 (de)
BG (1) BG64892B1 (de)
BR (1) BR9810904A (de)
CA (1) CA2297115C (de)
CO (1) CO4940422A1 (de)
CY (1) CY1107745T1 (de)
CZ (1) CZ302668B6 (de)
DE (1) DE69838066T3 (de)
DK (1) DK0998291T4 (de)
DZ (1) DZ2564A1 (de)
EA (1) EA003303B1 (de)
ES (1) ES2290989T5 (de)
GB (1) GB9715306D0 (de)
HK (1) HK1029272A1 (de)
HU (1) HU229119B1 (de)
ID (1) ID24198A (de)
IL (1) IL134045A0 (de)
IN (1) IN189035B (de)
MA (1) MA26522A1 (de)
MY (1) MY138246A (de)
NO (1) NO326356B1 (de)
NZ (3) NZ520652A (de)
OA (1) OA11632A (de)
PE (1) PE99799A1 (de)
PL (2) PL338127A1 (de)
PT (1) PT998291E (de)
SI (1) SI0998291T2 (de)
SK (2) SK287823B6 (de)
TR (1) TR200000135T2 (de)
TW (1) TW586926B (de)
UA (1) UA70302C2 (de)
UY (1) UY25103A1 (de)
WO (1) WO1999003476A1 (de)
ZA (1) ZA986365B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1897547A1 (de) * 1999-07-13 2008-03-12 Medicure Inc. Verwendung der Pyridoxalphosphatderivate zur Behandlung von Diabetes und Komplikationen davon
EP1832291A3 (de) * 1999-07-13 2009-11-04 Medicure Inc. Verwendung der Pyridoxalphosphat zur Behandlung von Diabetes und Komplikationen davon
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
CA2434169C (en) 2001-01-12 2011-03-15 Sun Pharmaceutical Industries Limited Spaced drug delivery system
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
JP2008019169A (ja) * 2004-10-25 2008-01-31 Osaka Univ 新規ｐｐａｒ調節剤およびそのスクリーニング方法
BRPI0620020A2 (pt) 2005-12-22 2011-10-25 Takeda Pharmaceutical preparação sólida, e, partìcula revestida

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5522636A (en) * 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
JPS5697277A (en) * 1980-01-07 1981-08-05 Takeda Chem Ind Ltd Thiazolidine derivative
JPS6051189A (ja) * 1983-08-30 1985-03-22 Sankyo Co Ltd チアゾリジン誘導体およびその製造法
US4582839A (en) * 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物
US4812570A (en) * 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
EP0842925A1 (de) * 1987-09-04 1998-05-20 Beecham Group Plc Substituierte Thiazolidindionderivate
US4791125A (en) * 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
WO1989008650A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione hypoglycemic agents
MX15171A (es) * 1988-03-08 1993-05-01 Pfizer Derivados de tiazolidinodiona hipoglicemicos
WO1991007107A1 (en) * 1989-11-13 1991-05-30 Pfizer Inc. Oxazolidinedione hypoglycemic agents
JPH04210683A (ja) * 1990-12-06 1992-07-31 Terumo Corp チアゾリジン−２，４−ジオン誘導体およびこれを含有する糖尿病合併症治療薬
US5183823A (en) * 1991-04-11 1993-02-02 Takeda Chemical Industries, Ltd. Pyridine n-oxide compounds which are useful as hypoglycemic and hypolipidemic agents
ATE139130T1 (de) * 1991-08-16 1996-06-15 Sandoz Ag Inhalator zur verabreichung von pulverförmigen substanzen
US5900435A (en) * 1991-08-26 1999-05-04 Pharmacia & Upjohn Company Composition, food product and uses of 3-guanidinopropionic acid
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
MA26522A1 (fr) 2004-12-20
PL338127A1 (en) 2000-09-25
SK288053B6 (sk) 2013-03-01
OA11632A (en) 2004-11-22
ATE366577T1 (de) 2007-08-15
HK1029272A1 (en) 2001-03-30
EP0998291B2 (de) 2011-07-06
AP2000001734A0 (en) 2000-03-31
DE69838066D1 (de) 2007-08-23
CA2297115A1 (en) 1999-01-28
DZ2564A1 (fr) 2003-02-15
DE69838066T3 (de) 2012-03-29
NZ501256A (en) 2002-09-27
JP2001510158A (ja) 2001-07-31
DE69838066T2 (de) 2008-03-20
EA003303B1 (ru) 2003-04-24
ES2290989T3 (es) 2008-02-16
AU8448798A (en) 1999-02-10
CZ302668B6 (cs) 2011-08-24
AR019331A2 (es) 2002-02-13
EA200000141A1 (ru) 2000-08-28
SI0998291T2 (sl) 2011-10-28
CO4940422A1 (es) 2000-07-24
AU743269B2 (en) 2002-01-24
CA2297115C (en) 2010-02-23
PT998291E (pt) 2007-10-11
DK0998291T3 (da) 2007-11-05
ZA986365B (en) 2000-01-17
ES2290989T5 (es) 2011-11-11
BG64892B1 (bg) 2006-08-31
IL134045A0 (en) 2001-04-30
NZ520652A (en) 2004-06-25
BR9810904A (pt) 2000-09-26
SK602000A3 (en) 2000-07-11
IN189035B (de) 2002-12-07
CZ2000173A3 (en) 2001-05-16
UY25103A1 (es) 2000-12-29
JP2005247865A (ja) 2005-09-15
PL199125B1 (pl) 2008-08-29
CN1264302A (zh) 2000-08-23
BG104139A (en) 2000-11-30
HU229119B1 (en) 2013-08-28
NO20000229D0 (no) 2000-01-17
HUP0003634A3 (en) 2003-04-28
TW586926B (en) 2004-05-11
DK0998291T4 (da) 2011-09-26
CY1107745T1 (el) 2013-04-18
KR100680667B1 (ko) 2007-02-09
TR200000135T2 (tr) 2000-05-22
NZ515555A (en) 2002-09-27
EP0998291B1 (de) 2007-07-11
UA70302C2 (uk) 2004-10-15
EP0998291A1 (de) 2000-05-10
MY138246A (en) 2009-05-29
GB9715306D0 (en) 1997-09-24
SI0998291T1 (sl) 2007-12-31
AR016768A1 (es) 2001-08-01
NO20000229L (no) 2000-01-17
KR20010021948A (ko) 2001-03-15
PE99799A1 (es) 1999-12-22
ID24198A (id) 2000-07-13
HUP0003634A2 (hu) 2001-07-30
NO326356B1 (no) 2008-11-17
AP1318A (en) 2004-10-22
WO1999003476A1 (en) 1999-01-28

Similar Documents

Publication Publication Date Title
EP1292300B1 (de) Zusammensetzungen zur behandlung von diabetes die einen dp iv-inhibitoren und einen andere antidiabetikum enthalten
SK286029B6 (sk) Farmaceutický prostriedok a jeho použitie
SK285484B6 (sk) Kombinácia obsahujúca 5-[4-[2-(N-metyl-N-(2- pyridyl)amino)etoxy]benzyl]tiazolidín-2,4-diónu, inzulínový sekrečný promótor a biguanidovú antihyperglykémickú látku, farmaceutický prostriedok s jej obsahom a ich použitie na liečbu diabetu
SK179399A3 (en) Use of insulin sensitiser and an insulin
JP2005247865A (ja) チアゾリジンジオンおよびスルホニル尿素を用いる糖尿病の治療
SK612000A3 (en) Application of insulin sensitiser, insulin secretagogue and alpha glucosidase inhibitor antihyperglycaemic agent for the treatment of diabetes mellitus and conditions associated with diabetes mellitus and a pharmaceutical composition
US20050054687A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
SK286028B6 (sk) Farmaceutický prostriedok a jeho použitie
SK179499A3 (en) The use of insulin sensitiser and alpha-glucosidase inhibitive antihyperglycaemic agent
US20020028768A1 (en) Treatment of diabetes with rosiglitazone and insulin
US20020045649A1 (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
MXPA00000631A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
MXPA99012065A (en) Treatment of diabetes with rosiglitazone and insulin
EA002659B1 (ru) Применение 5-[4-[2-(n-метил-n-(2-пиридил)амино)этокси]бензил]тиазолидин-2,4-диона для лечения гипергликемии
MXPA99012091A (en) Treatment of diabetes with thiazolidinedione and sulphonylurea
MXPA00003634A (en) Use of thiazolidinediones for the treatment of hyperglycaemia
CZ2000174A3 (cs) Farmaceutický prostředek proti diabetů mellitus a stavům s ním spojeným

Legal Events

Date Code Title Description
MK4A Patent expired

Expiry date: 20180716